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Molecular modelingrm of the Phosphorylase Kinase (PhK) α subunit (PHKA2 gene) cause X-linked
liver glycogenosis (XLG), the most frequent type of PhK deﬁciency (glycogen-storage disease type IX). XLG
patients can be divided in two subgroups, with similar clinical features but different activity of PhK
(decreased in liver and blood cells for XLG-I and low in liver but normal or enhanced in blood cells for XLG-
II). Here, we show that the PHKA2 missense mutations and small in-frame deletions/insertions are
concentrated into two domains of the protein, which were recently described. In the N-terminal
glucoamylase domain, mutations (principally leading to XLG-II) are clustered within the predicted
glycoside-binding site, suggesting that they may have a direct impact on a possible hydrolytic activity of
the PhK α subunit, which remains to be demonstrated. In the C-terminal calcineurin B-like domain (domain
D), mutations (principally leading to XLG-I) are clustered in a region predicted to interact with the regulatory
region of the PhK catalytic subunit and in a region covering this interaction site. Altogether, these results
show that PHKA2 missense mutations or small in-frame deletions/insertions may have a direct impact on the
PhK α functions and provide a framework for further experimental investigation.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
Phosphorylase Kinase (PhK; EC 2.7.11.19) is a large hexadecameric
complex made of four different subunits (αβγδ)4. It plays a key role in
the regulation of glycogenolysis, by catalyzing the phosphorylation
and activation of glycogen phosphorylase [1].
The catalytic activity of PhK is conferred by the γ subunit, and is
modiﬁed by the phosphorylation state of the large regulatory α and β
subunits, which together, account for approximately 4/5 of themass of
the holoenzyme and probably arose from gene duplication [2]. The
PhK γ subunit binds an intrinsic molecule of calmodulin, which
constitutes the δ subunit of the multimeric assembly. PhK has a
widespread tissue distribution and the α, β and γ subunits have
several tissue-speciﬁc isoforms. Some isoforms are encoded by
distinct genes, whereas other results from differential splicing of the
same gene [3,4]. Two genes (PHKA1 and PHKA2) encode the PhK α
subunit, one gene (PHKB) the PhK β subunit, two genes (PHKG1 andinked Liver Glycogenosis; CBL,
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ll rights reserved.PHKG2) the PhK γ subunit, whereas three genes (CALM1, CALM2 and
CALM3) encode for identical calmodulin proteins (δ subunit).
Deﬁciency of PhK results in glycogen-storage disease (GSD) type
IX. It is the most frequent inherited disorder of glycogen metabolism,
accounting for approximately 25% of all cases of GSDs (approximately
1/100,000 births) [4]. Mutations of the liver isoforms of PhK α or γ
subunits (PHKA2 and PHKG2 genes) cause liver-speciﬁc glycogenoses
[3,5,6]. X-linked liver glycogenosis (XLG) is the most frequent type of
PhK deﬁciency [7] and is caused by mutations in the PhK αL isoform
(PHKA2 gene) [3,5]. Mutations in the PhK αM isoform (PHKA1 gene)
cause X-linked muscle speciﬁc PhK deﬁciency [8–11], whereas
mutations in the ubiquitously expressed PhK β subunit (PHKB gene)
cause combined liver and muscle PhK deﬁciency [12,13].
XLG (caused by mutations in the PHKA2 gene) can be divided in
two subtypes, XLG-I and XLG-II, with patients having very similar
clinical symptoms (hepatomegaly and growth retardation during
childhood) but different in vitro enzyme deﬁciency. Patients with
XLG-I have indeed a deﬁciency in PhK activity in peripheral blood cells
and liver [7], whereas patients with XLG-II have normal PhK activity in
peripheral blood cells and variable activity in liver [14]. Interestingly, it
has been suggested that most of the XLG-I mutations, principally
inducing truncation or disruption of the protein, may lead to an
absence of the α subunit and/or to an unstable PhK complex. In
contrast, XLG-II mutations, which are missense mutations or small in
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α subunit and lead to in vivo deregulation of the holoenzyme [3,15]
(Table 1).
In the past, the sequences of the PhK α and β subunits have not
provided much insight into their possible functions. However, a few
years ago, Pallen predicted that their N-terminal extremities
correspond to glucoamylase-like domains (family 15 of glycoside
hydrolases [16]), suggesting a previously overlooked amylase activity
[17], which however still remains to be experimentally demon-
strated. More recently, we reported that the C-terminal domains
(that we called domains C and D) of PhK α ad β can be related to
calcineurin B-like (CBL) proteins [18]. These proteins, which are
members of the EF hand family, are involved in the regulation of
kinases of the CIPK/PKS family, and relieve autoinhibition of their
target kinases by binding to their regulatory region [19]. The
prediction that we made of CBL-like domains in the large regulatory
subunits of PhK provided new perspectives for understanding the
mechanism by which the “CBL-like” domain D of PhK α might
regulate the activity of the γ subunit, through a direct interaction
with its regulatory C-terminal region [20].
Interestingly, missense mutations (and small in-frame deletions/
insertions) affecting the PHKA2 gene are concentrated in either the
GH15-like domain and the CBL-like domain D of the protein (Table
1). In this study, we considered 3D structure models of these two
domains of PhK α, in order to predict the potential impact that these
mutations may have on its structure and/or function(s). The 3D
model of the GH15-like domain of PhK α was constructed on the
basis of a reﬁned alignment that we made here of the PhK α
sequence with a bacterial glucoamylase template, whereas the 3D
model of the PhK α CBL-like domain D originated from our previous
analysis [18].Table 1
Known missense mutations or small deletions/insertions in PhK αL subunit (PHKA2
gene), which lead to XLG-I and/or XLG-II
Mutation Type of XLG Reference
GH15-like domain
C91Y XLG-I [29]
Y116d XLG-I [30]
Y116–T120dup XLG-II [23]
H132Y XLG-II [25]
H132P XLG-II [25]
F141del XLG-I [31]
R186C XLG-II [3,15]
R186H XLG-II [25]
K189E XLG-II [5]
K189_T190del XLG-II [3]
G193V XLG-II [32]
T251del XLG-II [15]
R295H XLG-I/XLG-II [3]
R295C XLG-II [33]
D299G XLG-II [25]
P399S XLG-I [5]
CBL-like domain D
N953/L954I XLG-I [5]
R1070del XLG-I [23]
R1111_E1112insTR XLG-II [15]
M1113I XLG-I [23]
T1114I XLG-II [15]
E1125K XLG-I [3]
P1205L XLG-I [25,30,31]
G1207W XLG-I [5]
G1210E XLG-I [29]
Other domains
P498L XLG-II [23]
I566N XLG-I [34]
Q818_Y825del8 XLG-I [5]
P869R XLG-I [23]
R916W XLG-I [23]
The small in-frame deletions (del), insertions (ins) and duplications (dup) are indicated
in italics.2. Material and methods
Models of the three-dimensional structures of the PhK α and β
GH15-like domains and CBL-like domains D were constructed as
described in Supplementary data 1. Three-dimensional structures
were visualized using Swiss-PdbViewer [21].
3. Results and discussion
3.1. The GH15-like domain of PhK α and β: modeling and analysis of the
putative active sites
The GH15-like domains of the PhKα and β subunits were modeled
on the basis of the alignment shown in Fig. 1, using the experimental
structure of the glucoamylase from Clostridium thermosaccharolyticum
as template (pdb 1LF9, see Supplementary data 1 for details of the
procedure). Glucoamylases adopt a characteristic (α/α)6 barrel
structure (also known as six-helical hairpin toroids) [22] (Fig. 2).
Helical hairpins are arranged into a two-layered toroid (with helices of
the inner and outer layers designated, in Figs. 1 and 2, “int” and “ext”,
respectively). Long loops connect external (outer) with internal
(inner) helices, forming at one end of the toroid a narrow pocket in
which the substrate binds. In contrast, connecting loops on the other
end of the toroid (thus connecting internal with external helices) are
relatively short, and do not protrude from the toroid core. GH15-like
domains of the PhK α and β subunits share these features, with a
particular good sequence conservation of loops connecting external
with internal helices, forming the walls of the active site (Fig. 1).
Noteworthy is that the small β-strands or extended regions existing in
these loops are particularly well conserved. Only the loop linking helix
ext1 with helix int1 is smaller in the PhK α and β subunits than in the
1LF9 template (Fig. 1). The loop linking helix int3 with helix ext4 is
also smaller (with the two helices being probably smaller), but this
region, which is the most difﬁcult to align with accuracy, is located
opposite to the predicted active site (Fig. 1).
In glucoamylases, two acidic residues (E438 and E636 in 1LF9)
directly participate in the hydrolysis of the glycosidic bond of the non-
reducing end of polysaccharides through a general acid-base
mechanism [16]. As shown in Fig. 2 and Table 2, the GH15-like
domain of the PhK α subunit conserves not only these two catalytic
residues, but also most of the residues contacting the substrate in the
active site (black circles up to the 1LF9 sequence on Fig. 1), among
which several aromatic amino acids can be found. This suggests, as
already hypothesized by Pallen [17], that this domain might have a
catalytic activity, even though to our knowledge, this activity has not
yet been experimentally demonstrated. It is interesting to note that
the aromaticity of the substrate-binding pocket is likely increased in
the PHK α and β GH15-like domains, as three residues of the bacterial
glucoamylase template (1LF9 G392, L602 and E605) are substituted by
aromatic residues (H132, F331 and Y334 in PHK α; H169, F368 and
Y371 in PhK β; highlighted with the symbol “+” in Fig. 1 and colored
salmon in Fig. 2). The glucoamylase (1LF9) L652, which directly
contacts the substrate (Fig. 2 and Table 2), is also substituted by an
aromatic residue in PhK (H400 in PHK α and F441 in PhK β).
In contrast to PHK α, the GH15-like domain of the PhK β subunit
lacks some of the active site residues, in particular a glutamic acid (E),
whichwould assist thehydrolysis byactingas abase. This one is replaced
in PhK β by a lysine (K408, Figs. 1 and 2, Table 2). These features suggest
that the PhK β subunit might be devoid of catalytic activity and thereby,
might rather play a regulatory role relative to the PhK α subunit.
3.2. Mapping of disease-causing mutations (missense and small
in-frame deletions/insertions)
Most of the missense mutations (amino acid substitutions) and
small deletions (del), duplications (dup) and insertions (ins) in the
Fig. 1. Alignment of the sequences of the GH15-like domains of the PhK α and β subunits (PHKA1 (KPB1), PHKA2 (KPB2) and PHKB (KPBB) genes) with the GH15 domain of the
Clostridium thermosaccharolyticum glucoamylase, whose 3D structure is known (pdb 1LF9, [22]). The observed secondary structures of the glucoamylase are reported up to its
sequence, with external and internal helices labeled « ext » and « int », respectively. This alignment was reﬁned using Hydrophobic Cluster Analysis (HCA), as described in the
Supplementary data 1. Sequences identities are shownwhite on a black background, whereas similarities between hydrophobic amino acids (VILFMYWW) or amino acids which can
substitute them in a context-dependent way (ACTS for aliphatic residues, or H for aromatic residues) are shaded grey. Other similarities are boxed. Amino acids participating in the
1LF9 glucoamylase active site are numbered and highlighted with black circles. Amino acids mutated in the PHKA2 gene are numbered and highlighted with black stars. G223 and
D299 mutated in the PHKA1 gene (G223R and D299V, see text) are indicated with grey stars, whereas the amino acid substitutions in the PHKB gene are indicated with white stars.
Small deletions and an insertion (duplication) in the PHKA2 gene are underlined and highlighted with pentagons.
666 C. Carrière et al. / Biochimica et Biophysica Acta 1782 (2008) 664–670PHKA2 gene are concentrated within the GH15-like domain and the
CBL-like domain D (Table 1). Indeed, only four missense mutations
and an in-frame deletion of eight amino acids were described outside
these domains.
3.2.1. The GH15-like domain of PhK α
We mapped the known PHKA2 missense mutations in the GH15-
like domain (Table 1) on the corresponding 3D model (Figs. 1 (black
stars) and 3). Remarkably, all of them are located in the long loops
connecting the external with the internal helices, and are located in
close proximity, if not corresponding to the residues contacting the
substrate in the predicted active site. Indeed, R186 and R295 are
aligned with 1LF9 E439 and R575 (Table 2, Figs. 1 and 3), whose side
chain atoms make close contacts with acarbose in the experimental
structure of glucoamylases [22]. C91/Y116/H132, K189/G193, D299
and P399 are located in close proximity of the substrate-binding
pocket residues of the ext2–int2, ext3–int3, ext5–int5 and ext6–int6
loops, respectively (Fig. 3). H132 corresponds to one of the « new »aromatic residue of the substrate-binding pocket (see before) and
is located two residues downstream the 1LF9 W390/PhK α W130
(Fig. 1).
Thus, most of the missense mutations observed in the GH15-like
domain of PhK α lie within its predicted substrate-binding site. Only
C91, Y116 and P399 are located a little farther (Fig. 3). However, one
might expect that the mutation of P399 in a serine would lead to a
local perturbation of the conformation of the loop and consequently
of the two residues located one and three positions downstream
(H400 and W402), which directly contact the substrate. C91 and
Y166 are also located farther, but always make part of the large
surface displayed at one end of the α/α barrel core. Thus, they may
be also involved in substrate recognition, although they are more
distant from the active site. In this respect, it is worth noting that
the substitutions of C91, Y116 and P399 are the missense mutations
in the GH15-like domain that are exclusively associated with XLG-I
(and not XLG-II; R295H being associated with XLG-I and XLG-II).
This suggests that in contrast to other mutations which might
Fig. 2. The active site of GH15 and predicted active-sites of GH15-like domains (PhK α and β subunits). On top are shown two orthogonal views of the 3D structure of the Clostridium
thermosaccharolyticum glucoamylase GH15 domain (ribbon representation pdb 1LF9, [22]), in complexwith acarbose (in green). Amino acids participating in the glucoamylase active
site are shown in atomic details. At the bottom is shown the comparison of the active site of the experimental structure of the Clostridium thermosaccharolyticum glucoamylase GH15
domain (1LF9) with the predicted ones in the 3D models of the PhK α (liver isoform, PHKA2 gene) and β (PHKB gene) GH15-like domains. The two catalytic glutamate residues are
depicted in red, and the acarbose molecule in green. Amino acids that are not strictly conserved in PhKα or β relative to 1LF9 are underlined and labeled in purple. The four aromatic
residues increasing the aromatic character of the predicted substrate-binding site of PhK α and β are colored salmon.
Table 2
Amino acid residues contacting the substrate in the active sites of GH15 (1LF9) and in
the potential active site of GH15-like (PhK α and β) domains
1LF9 PHKA1 PHKA2 PHKB
Ext1–int1 Y337 Q39 Q39 Q80
W341 W43 W43 K83
R343 R45 R45 Q85
D344 D46 D46 D86
Ext2–int2 Q380 T120 T120 T157
W390 W130 W130 Y167
Ext3–int3 W437 W184 W184 W221
E438 E185 E185 E222
E439 R186 R186 R223
Ext5–int5 R575 R295 R295 R332
W599 W329 W329 F365
Ext6–int6 E636 E371 E371 K408
L652 H400 H400 F441
W654 W402 W402 W443
The GH15 experimental structure (pdb 1LF9) has been solved in complex with
acarbose, a potent glucoamylase inhibitor. The residues contacting the substrate are
indicated with a black circle up to the 1LF9 sequence in Fig. 1. The glutamic acids
(E) acting (or predicted to act) as the catalytic acid (ext3–int3) and base (ext6–int6)
are underlined.
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might rather affect its structure.
Two small deletions of one and two amino acids (T251del [15]
and K189–T190del [3], respectively) and a duplication (Y116–
T120dup [23]), are also associated with XLG-II, in addition to
most of the missense mutations reported above. The two amino
acid deletion involves one amino acid (K189), which is also the
target of a missense mutation (see above). Interestingly, Y116–T120
and T251 are located in the ext2–int2 and ext4–int4 loop,
respectively, thus also within the predicted substrate-binding
pocket (Fig. 3). In contrast, the deletion of F141 is associated with
XLG-I. Accordingly, this amino acid is localized buried within helix
int2 (Figs. 1 and 3), and it is likely that its mutation impairs the
folding or the fold stability of the GH15-like domain, rather than its
predicted function.
Finally, we completed this mutation mapping by reporting on the
3D models the missense mutations observed in PHKA1 (X-linked
muscle-speciﬁc PhK deﬁciency). In contrast to PHKA2, only a few
mutations have been reported for PHKA1. There is to our knowledge
only two missense mutations in PHKA1, corresponding to the D299V
[9] and G223R [24] substitutions. Interestingly, the mutation of the
same D299 in glycine in PHKA2 leads to XLG-II [25] (see above).
G223 is also located in the long loops connecting the external with
the internal helices, but farther from the substrate-binding site
(Supplementary data 2, left view).
In PHKB (autosomal recessive PhK deﬁciency of liver and muscle),
there is, to our knowledge, only two missense mutations (A118P and
M185I) in the GH15-like domain [12,23]. Interestingly, both residues
are located in close proximity, buried within the (α/α)6 toroid coreof the PhK β GH15 model (A118 within helix ext2, M185 at the end
of helix int2, Supplementary data 2, right view). This observation
suggests that mutation of these amino acids would disturb the
folding and stability of the domain. Thus, in contrast to what is
observed for PHKA1 and PHKA2, these PHKB missense mutations do
not likely directly affect a potential function of this subunit, but
rather its structure.
Fig. 3.Missense mutations and small in-frame deletions/duplication within the GH15-like domain of the PhK α subunit (PHKA2 gene). Top: the predicted active site is viewed in the
same orientation as in Fig. 2, with the active site residues depicted in atomic details. Amino acids that are the targets of missense mutations or small in-frame deletions (T251del,
F141del) are labeled and shown in a van der Waals representation. The position of Y116–T122 duplication (dup) is shown as a purple ribbon. Bottom: two orthogonal views of the
location of the same missense mutations or small in-frame deletions within the context of the whole domain (shown in a ribbon representation).
Fig. 4. Missense mutations and small in-frame deletions/insertion within the CBL-like
domainDof thePhKα subunit (PHKA2gene).Molecular surfaceof themodel of theCBL-like
domain D of PhKα, at the exception of the C-terminal extension of this domain, shown in a
ribbon representation (green). This C-terminal extension shields the hydrophobic groove,
which likely interacts with the regulatory domain of the target kinase (the PhK γ subunit).
The six known missense mutations are colored red (the three located in the groove) and
orange (the three lying in the C-terminal extension). The solvent accessible surface of R1111,
afterwhicha twoamino acid insertionoccurs (R1111_E1112insTR), andofN953/L954,which
are replaced by an isoleucine after a trinucleotide deletion (N953/L954I) are shown in pink.
The side chain of R1070 (R1070del) is shown in blue. The large insertion occurring between
helices αB and αC, which has not been modeled, is symbolized with a star.
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The six missense mutations that have been reported in the CBL-
like domain D of PHKA2 principally lead to XLG-I (Table 1). This
contrasts with missense mutations associated with the GH15-like
domains, which mainly lead to XLG-II. Interestingly, the mapping of
the six mutated amino acids on the 3D models we previously made of
the CBL-like domain D [18] led us to observe that they are also
clustered in the same region, making part of the hydrophobic groove
(M1113, T1114, E1125) and in the C-terminal extension shielding the
hydrophobic groove (P1205, G1207, G1210) (Fig. 4). The in-frame
insertion of two amino acids (R1111_E1112insTR), as well as the
trinucleotide deletion leading to the replacement of two amino acids
by one new residue (L953–N954I) also occur within the hydrophobic
groove (Fig. 4). By analogy with the known CIPK/CBL system [26–28],
this hydrophobic groove might be able to interact with the regulatory
domain of the kinase subunit (γ subunit), which would take the place
occupied in the uncomplexed state by the C-terminal extension of the
domain. It is thus likely that mutations in this hydrophobic groove or
in the C-terminal extension covering this groove when not interact-
ing with the γ subunit, dramatically impair the interaction with the
kinase and thus the PhK function. The small in-frame deletion of one
amino acid (ΔR1070, Table 1) lies outside this active site, but it is
likely that this deletion alters either the domain fold (as R1070 is
located within a regular secondary structure (helix F1[18])) or the
function of the large insertion included in this domain and containing
the multiphosphorylation sites.
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Out of the remaining mutations (Table 1), two missense
mutations (P869R, R916W) and the eight amino acid deletion
(Q818_Y825del) are located into domain C, which was predicted to
also have a CBL-like architecture [18]. The modeling of this domain is
however more difﬁcult to perform given the very low levels of
sequence identities with domain D and with CBL proteins. Sequence
analysis however predicted that P869 and R916 are included within
helices (buried in helix E3 and solvent exposed in helix E4,
respectively), without being involved in a hydrophobic groove, as
for domain D (data not shown). The eight amino acid deletion
(Q818_Y825del) might lead to the absence of helix F1 (data not
shown), and thus to a disrupted domain structure. The two last
missense mutations (P498L, I566N) are included in domain B, which
remains to be deciphered.
3.3. Conclusions
In contrast to XLG-I mutations, which result in a truncated or
disrupted α subunit and/or in an unstable holoenzyme, XLG-II
mutations are thought to have a minor impact on the structure of the
protein. It has been hypothesized that several of them may be
involved in the regulation of PhK by phosphorylation of the α
subunit [15]. Although such an hypothesis cannot be completely
ruled out, we clearly show here that the known missense mutations
leading to XLG-II are principally clustered into the predicted active
site of the PhK α GH15-like domain. They thus might have a direct
impact on the predicted hydrolytic activity of the α subunit, which
however remains to be demonstrated. The likelihood of such an
activity is otherwise reinforced by the present mapping of glyco-
genosis-inducing mutations. Missense mutations associated with the
PhK α CBL-like domain D, which principally lead to XLG-I, are
clustered in the region predicted to interact with the regulatory
domain of the catalytic subunit and in a region covering this
interaction site. Therefore, they probably lead to an unstable or less
regulated holoenzyme, as the α–γ interaction has been suggested to
modulate and/or increase the afﬁnity of the catalytic subunit for
calmodulin [18].
Altogether, these ﬁndings open new perspectives for under-
standing the molecular mechanism(s) by which the PhK α subunit
may regulate the holoenzyme activity andmay lead, whenmutated, to
PhK deﬁciencies.
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